Record-high quarterly revenue driven by robust export growth of its key products, including injectables, dermal fillers, and cosmetics

Huons Global (co-CEOs Yoon Sung-tae and Song Soo-young) reported on August 14 its consolidated financial results for the second quarter of this year. Huons Global reported consolidated revenue of 212.7 billion won, operating profit of 25.3 billion won, and net profit of 11.5 billion won, reflecting year-over-year changes of +1.4%, -16.9%, and -50.0%, respectively.

Huons Global posted record quarterly revenue on a consolidated basis in the second quarter of this year compared to the same period last year. Huons Global`s operating profit saw a decline in the quarter, primarily due to softened performance from its aesthetic subsidiary companies, including Humedix and Huons BioPharma, amid intensifying domestic competition in botulinum toxin market.

Huons Global`s strategic investment in Research and Development (R&D) to secure future growth engines also contributed to the lower operating profit. The Group`s R&D expenses for the first half of this year increased by 4% to 34 billion won from 32.7 billion won in the same period last year. The R&D expenses as a percentage of revenue also expanded to 8.2% from 7.9%.

For six months ended June 30, 2025, Huons Global reported its consolidated revenue of 411.8 billion won and operating profit of 50.8 billion won, achieving a record-breaking revenue for both quarterly and semi-annual periods.

Huons (CEO Song Soo-young) reported consolidated sales of 156 billion won, operating profit of 13.1 billion won, and net profit of 11.8 billion won, up 4.7%, 40.3%, and 46.5%, respectively. The second quarter saw Huons` revenue exceed 150 billion won, achieving a new quarterly record and extending the company`s momentum in profitability improvement.

By business segments, Ethical Drug (ETC) business showed solid results of 69.2 billion won, driven by continued sales growth in chronic disease drugs and increased exports of injectable products. Beauty and well-being business decreased to 42.2 billion won, affected by the spin-off and revenue transfer of its health functional food business to Huons N since May. The revenue of beauty and well-being business excluding health functional food totaled to 37 billion won, up 7.7% year-over-year. The continuous glucose monitor system, Dexcom G7, posted record-high quarterly revenue. Huons posted 20.7 billion won in Contract Manufacturing Organization (CMO) business, due to increased operating rate of the eye drop line at the second plant.

Huons significantly improved its profitability compared to the same period last year as a result of continuous cost management efforts and improved performances from subsidiary companies.

Huons’ subsidiary company, Huons N reported revenue of 18.7 billion won, up 76.7% year-over-year. HuonsLifeSciences posted 6.4 billion won in revenue, up 29.5% compared to the same period last year. PanGen Biotech, acquired by Huons in the end of last year, was incorporated as a subsidiary subject to consolidation starting in June of this year.

Humedix (CEO Kang Min-jong), an aesthetic subsidiary of Huons Group, reported its second quarter separate revenue of 43 billion won, operating profit of 10.8 billion won, and net profit of 7.9 billion won, with year-over-year changes of -6.3%, -17.3%, and -33.5%, respectively. The company’s key business, which is filler exports, continued its growth momentum and cosmetics exports increased significantly. Accordingly, overseas aesthetics sales recorded strong results; however, domestic filler, toxins and CMO for ETC sales slowed down.

Humedix’s overseas business showed strong performance every quarter, primarily driven by stable sales in China and significant increase in filler sales in Brazil and South America. Cosmetic sales soaring in China, Vietnam, and Japan also contributed to the robust export growth.

In addition, the sales increase of Elravie Re2O contributed to a partial recovery from the decline in toxin sales. Humedix anticipates further sales increases in the second half of the year, driven by enhanced academic marketing initiatives such as symposiums.

HuM&C (CEO Lee Choung mo), a subsidiary specialized in healthcare subsidiary materials, reported its second quarter consolidated revenue of 13.4 billion won, operating profit of 777 million won, and net loss of 34 million won, with year-over-year changes of +21.8%, -40.3%, and -103.2%, respectively.

HuM&C’s glass business recorded revenue of 9.1 billion won, an 11.4% increase from the same period last year. The cosmetics business recorded revenue of 4.2 billion won, up 52.4% year-over-year. An increase in raw materials cost led to decreased profitability. HuM&C expects ramp up of its production capacity of medical device containers such as ampoules and vials with its production facility’s operation in Vietnam, which began in the second quarter.

Huons BioPharma, a subsidiary specializing in botulinum toxin, reported its second quarter revenue of 7.8 billion won and operating profit of 311 million won, showing negative growth compared to the same period last year. The decrease was attributed to weakened domestic sales of toxin products since the second half of last year. Compared to the previous quarter, it showed healthy growth in domestic sales and exports by 4.1% and 13.7%, respectively.

Huons Meditech, a medical device subsidiary, recorded revenue of 14.3 billion won and an operating profit of 462 million won. Food Assemble, a subsidiary specialized in meal kits, recorded revenue of 2.1 billion won and an operating loss of 389 million won.

Huonslab is actively engaged in R&D on recombinant human hyaluronidase. The company completed patient enrollment in its pivotal phase 1 clinical trial in Korea on May. Following the completion of the trial, Huonslab plans to apply for Ministry of Food and Drug Safety (MFDS) approval within this year. Huonslab is also actively securing its intellectual property rights, including the formulation patent for the formulation without serum albumin of recombinant human hyaluronidase in South Korea last month.

Meanwhile, Huons Global approved a cash dividend of 130 won per share and set the record date for the dividend as August 21, at its board of directors meeting on August 6. The company official said that the cash dividend was declared in consideration of rapidly changing business environment, but still on track for an increasing trend of total annual dividend including year-end dividend, up to 30% compared to the previous year.

The capital reserve reduction and reduced dividends approved at this year’s annual general meeting of shareholders do not apply to the interim dividend, but will take effect from the year-end dividend. If the year-end dividend increases, shareholders are expected to benefit from greater tax-exempt dividends.

Huons Global CEO Song Soo-young said, “Huons Group pursues an aggressive export expansion strategy and continued investment in R&D despite domestic and international economic downturn and external uncertainties. We will make our best efforts to secure both tangible outcomes and mid- to long-term growth momentum.”